Optimize Model Selection, Accelerate Timelines, Improve Predictivity of Toxicity

Dates: May 12-14 | Location: Boston, MA

Why Attend

With nearly 90% of drug candidates failing in the clinic and one-third of those failures driven by safety preclinical toxicology has reached a critical inflection point. Traditional models are no longer sufficient to predict human risk, leading to costly late-stage attrition and stalled pipelines.

The 2026 summit marks a new era for toxicology. Following the FDA’s 2025 roadmap to reduce reliance on animal testing, adoption of New Approach Methodologies (NAMs), including in vitro, microphysiological, and computational models, is accelerating. CROs and technology developers are releasing innovative platforms, but challenges remain around predictivity, validation standards, and regulatory alignment.

What You’ll Learn

This industry-led forum is the only meeting dedicated to benchmarking what truly works in predictive toxicology. Key focus areas include:

• Evaluating in vivo, in vitro, and in silico strategies
• Sharing real IND case studies
• Defining fit-for-purpose model selection across modalities
• Advancing NAM adoption while ensuring regulatory compliance

Who Should Attend

If you are responsible for:

• De-risking first-in-human decisions
• Implementing innovative toxicology strategies
• Improving safety translation from preclinical to clinic

…this summit is your essential forum to separate innovation from hype and build strategies that stand up both clinically and regulatorily.

📥 Download the Event Guide to explore the full agenda, speakers, and registration details:

Organiser Name: Hanson Wade
Contact: Nisha Poyser-Reid
info@hansonwade.com
(+1) 617 455 4188